- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Hammers on the Potential Utility of HIF-2α Inhibitors in RCC
Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Hans Hammers, MD, PhD, an associate professor of internal medicine in the Division of Hematology-Oncology at The University of Texas Southwestern Medical Center, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma (RCC).
HIF-2α inhibitors are emerging agents that could transform the treatment paradigm of RCC, says Hammers. One compound called belzutifan (MK-6482) has demonstrated significant potential in this setting, Hammers explains.
According to updated findings from a phase 1/2 study (NCT02974738), belzutifan induced an overall response rate of 25% and a disease control rate of 80% in patients with advanced clear cell RCC. Regarding safety, anemia and hypoxia were the most commonly reported grade 3 adverse effects, concludes Hammers.
Related Content:
